Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $4.62B
• Dividend Yield: N/A
• Average Volume (3M): 1.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: -21.96%
• Country: US
• Employees: 437
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.38
• Shares Outstanding: 94,891,840
• 10 Day Avg. Volume: 1,125,820
• 30 Day Avg. Volume: 1,186,784
• PEG Ratio: 0.00
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 3975.39
• P/FCF Ratio: -17.97
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 2.52K
• Enterprise Value/Gross Profit: 2.52K
• Enterprise Value/Ebitda: -8.15
• 1Y Price Target: $83.73
• Price Target Upside: 71.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -5
• Revenue Forecast (FY): $5.13M

• Rating: 61 Neutral
• Price Target: $50.00 ▲(2.65% Upside)

Crinetics Pharmaceuticals' overall stock score is driven by the successful launch of PALSONIFY and positive technical indicators, suggesting potential growth. However, financial challenges and valuation concerns due to ongoing losses and a negative P/E ratio temper the outlook. The strong financial position and FDA approval provide a solid foundation for future performance.

Positive Factors

FDA Approval of PALSONIFY

The FDA approval of PALSONIFY strengthens Crinetics' market position in endocrine treatments, promising long-term revenue growth from a new product line.

Strong Financial Position

A robust cash position ensures operational funding into 2029, providing stability and enabling strategic investments in R&D and market expansion.

Pipeline Development

Advancement in the CRN09682 study highlights Crinetics' innovative pipeline, potentially expanding its market reach and addressing unmet medical needs.

Negative Factors

Operational Losses

Ongoing operational losses indicate challenges in achieving profitability, which may limit financial flexibility and long-term sustainability.

Delayed Programs

Delays in key programs could hinder future growth and market competitiveness, affecting the company's ability to capitalize on new opportunities.

Negative Cash Flow

Negative cash flow poses liquidity risks, potentially impacting Crinetics' ability to fund operations and invest in growth initiatives.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

How the Company Makes Money

Crinetics Pharmaceuticals generates revenue through a combination of grants, collaborations, and potential product sales. The company typically engages in strategic partnerships with larger pharmaceutical companies to co-develop its drug candidates, which can provide upfront payments and milestone payments as clinical and regulatory milestones are achieved. Additionally, once products receive regulatory approval, the company can earn revenue through sales in the market. Moreover, Crinetics may also receive royalties from its partners based on sales of products developed through their collaborations, thereby diversifying its revenue streams.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Crinetics Pharmaceuticals faces significant financial challenges, with persistent operational losses and cash flow issues. While recent financing has strengthened the cash position, the company's ability to generate sustainable revenue and profit remains unproven. The balance sheet shows improvement, but historical financial instability highlights the need for caution.

Income Statement

Crinetics Pharmaceuticals has experienced fluctuating revenue with a decline from 2022 to 2023, followed by a sharp drop in 2024. The gross profit margin is consistently high, but net losses persist, indicating ongoing profitability challenges. Negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The company shows a strong equity position with substantial cash reserves and minimal debt. However, negative stockholders' equity in earlier years indicates past financial distress. Current liabilities are relatively low, but the debt-to-equity ratio is a concern due to historical negative equity.

Cash Flow

Operating cash flow remains negative, highlighting potential liquidity challenges. Free cash flow is also consistently negative, though recent financing activities have bolstered cash reserves. Stability in cash flow remains a concern with ongoing operational losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.53M	1.04M	4.01M	4.74M	1.08M	71.00K
Gross Profit	1.53M	1.04M	4.01M	4.74M	1.08M	-56.93M
EBITDA	-474.16M	-336.07M	-221.51M	-166.90M	-106.78M	-74.00M
Net Income	-423.10M	-298.41M	-214.53M	-163.92M	-107.64M	-73.81M
Balance Sheet
Total Assets	1.20B	1.43B	635.35M	352.18M	351.01M	183.44M
Cash, Cash Equivalents and Short-Term Investments	1.09B	1.35B	558.55M	334.43M	333.71M	170.88M
Total Debt	49.14M	51.72M	51.73M	3.08M	3.07M	4.01M
Total Liabilities	123.86M	109.79M	96.25M	35.85M	19.07M	14.53M
Stockholders Equity	1.07B	1.32B	539.11M	316.33M	331.94M	168.92M
Cash Flow
Free Cash Flow	-356.03M	-229.81M	-171.00M	-116.86M	-89.02M	-62.21M
Operating Cash Flow	-349.69M	-225.97M	-166.31M	-115.20M	-88.59M	-62.03M
Investing Cash Flow	-425.29M	-574.82M	-200.41M	-173.98M	-56.48M	217.00K
Financing Cash Flow	568.61M	1.01B	388.94M	121.96M	252.68M	114.57M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Positive. The current price of 48.71 is above the 20-day moving average (MA) of 47.58, above the 50-day MA of 44.56, and above the 200-day MA of 35.54, indicating a bullish trend. The MACD of 1.26 indicates Positive momentum. The RSI at 57.62 is Neutral, neither overbought nor oversold. The STOCH value of 74.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRNX	61 Neutral	$4.62B	-10.74	-44.42%	―	―	-21.96%
LGND	60 Neutral	$3.88B	94.89	5.42%	―	64.83%	-9.12%
AKRO	60 Neutral	―	―	-34.53%	―	―	-0.06%
RARE	57 Neutral	$3.34B	-5.82	-325.76%	―	20.63%	8.09%
KYMR	56 Neutral	$6.56B	-23.11	-32.09%	―	-50.05%	-54.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
APLS	50 Neutral	$3.18B	84.74	14.10%	―	42.11%	―

Crinetics Pharmaceuticals Corporate Events

Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY

On September 25, 2025, Crinetics Pharmaceuticals announced that the FDA approved PALSONIFYTM (paltusotine) for the first-line treatment of adults with acromegaly who had an inadequate response to surgery or for whom surgery is not an option. PALSONIFY, a once-daily oral therapy, marks a significant advancement in acromegaly treatment, offering a non-invasive alternative to traditional injections. The approval is based on successful Phase 3 trials demonstrating the drug’s efficacy and safety, and it represents a pivotal milestone for Crinetics as it enhances its position as a leader in endocrine-focused pharmaceuticals. The company is also working to ensure broad access to PALSONIFY and has launched a support program, CrinetiCARE, to assist patients throughout their treatment journey.